Endomedix has developed a platform technology called PLEXimine™ based on novel polysaccharide chemistry that can produce an array of different properties for use in the development of a series of separate product categories. The company has been awarded 7 NIH SBIR & 1 NYS grants, and has obtained 9 issued patents based on this technology. The first device using this technology will be PlexiClot™ Absorbable Hemostat for brain & spinal surgeries, an underserved $1.7B niche. Additionally, the Company has entered into a Cooperative Research and Development Agreement (CRADA) with the US Army Medical Materiel Development Command (USAMMC) for the development of a treatment system for ocular projectile battlefield trauma using PLEXimine technology. The company has raised $3.3 M in private investment.